Understanding Amenorrhea
A Comprehensive Clinical Guide for Healthcare Professionals
Professor Mykhailo Medvediev
Based on UpToDate Clinical Decision Support | www.uptodate.com
Introduction
What is Amenorrhea?
Amenorrhea represents the absence of menstruation and can be a transient, intermittent, or permanent condition. It results from dysfunction at various levels of the reproductive axis: hypothalamus, pituitary, ovaries, uterus, or vagina.
Understanding amenorrhea requires a systematic approach to identify the underlying cause and provide appropriate management. This condition affects women across all age groups and can have significant implications for fertility, bone health, and overall well-being.
Source: UpToDate - Causes of Primary Amenorrhea | www.uptodate.com
Classification of Amenorrhea
Primary Amenorrhea
Absence of menarche by age 15 years in the presence of normal growth and secondary sexual characteristics
  • Evaluation begins at age 13 if no secondary sexual characteristics
  • Usually genetic or anatomical abnormalities
Secondary Amenorrhea
Absence of menses for >3 months in women with regular cycles or >6 months with irregular cycles
  • More common than primary amenorrhea
  • Multiple potential etiologies
Source: UpToDate - Epidemiology and Causes of Secondary Amenorrhea | www.uptodate.com
Epidemiology
Prevalence and Distribution
Understanding the epidemiology of amenorrhea helps clinicians prioritize differential diagnoses and allocate resources effectively.
35%
Hypothalamic Causes
Primarily functional hypothalamic amenorrhea
40%
Ovarian Causes
30% PCOS, 10% primary ovarian insufficiency
17%
Pituitary Causes
13% hyperprolactinemia, others rare
7%
Uterine Causes
All due to intrauterine adhesions
Source: UpToDate - Epidemiology and Causes of Secondary Amenorrhea | www.uptodate.com
Primary Amenorrhea: Key Etiologies
Primary amenorrhea is usually the result of genetic or anatomical abnormalities. A large case series identified the following distribution:
Gonadal dysgenesis, including Turner syndrome, represents the most common cause, accounting for 43% of cases.
Source: UpToDate - Causes of Primary Amenorrhea | www.uptodate.com
Hypothalamic
Hypothalamic Causes of Amenorrhea
Hypothalamic dysfunction represents a significant proportion of amenorrhea cases, with functional hypothalamic amenorrhea being the most common.
Functional Hypothalamic Amenorrhea
Characterized by abnormal GnRH secretion leading to decreased gonadotropin pulsations and low estradiol
  • Weight loss and eating disorders
  • Excessive exercise
  • Psychological stress
Isolated GnRH Deficiency
Rare congenital condition (Kallmann syndrome if with anosmia)
  • Prepubertal low gonadotropins
  • Genetic mutations identified
Structural Lesions
Tumors and infiltrative diseases
  • Craniopharyngioma
  • Langerhans cell histiocytosis
  • Sarcoidosis
Source: UpToDate - Functional Hypothalamic Amenorrhea | www.uptodate.com
Functional Hypothalamic Amenorrhea: Risk Factors
Energy Deficit States
  • Eating disorders (anorexia nervosa)
  • Excessive exercise relative to caloric intake
  • Weight loss >10-15% of ideal body weight
  • BMI <18.5 kg/m²
Other Contributing Factors
  • Psychological stress
  • Chronic systemic illness
  • Type 1 diabetes mellitus
  • Celiac disease
Multiple factors may contribute to functional hypothalamic amenorrhea, with the common pathway being disruption of GnRH pulsatility due to negative energy balance.
Source: UpToDate - Functional Hypothalamic Amenorrhea: Pathophysiology | www.uptodate.com
Pituitary
Pituitary Causes of Amenorrhea
Hyperprolactinemia
Most common pituitary cause (13% of secondary amenorrhea)
  • Prolactinomas (micro/macroadenomas)
  • Medications (antipsychotics, metoclopramide)
  • Hypothyroidism
Other Sellar Masses
Non-functioning pituitary adenomas and other tumors
  • Craniopharyngiomas
  • Meningiomas
  • Rathke's cleft cysts
Pituitary Dysfunction
Structural or functional impairment
  • Sheehan syndrome
  • Lymphocytic hypophysitis
  • Hemochromatosis
Source: UpToDate - Causes of Hyperprolactinemia | www.uptodate.com
Hyperprolactinemia: Diagnostic Approach
Serum prolactin above the normal range (typically 15-20 ng/mL) requires careful evaluation. Stress, sleep, exercise, and meals can transiently elevate prolactin.
01
Initial Measurement
Random serum prolactin level
02
Confirm Elevation
Repeat if <50 ng/mL (fasting, morning, no exercise)
03
Rule Out Hypothyroidism
Measure TSH in all cases
04
Pituitary Imaging
MRI if confirmed elevation or >50 ng/mL
Source: UpToDate - Clinical Manifestations and Evaluation of Hyperprolactinemia | www.uptodate.com
Ovarian
Ovarian Causes: Gonadal Dysgenesis
Gonadal dysgenesis caused by chromosomal abnormalities is the most common cause of primary amenorrhea, resulting in premature depletion of ovarian oocytes and follicles.
Turner Syndrome (45,X)
55-60% have complete absence of one X chromosome
  • Accelerated oocyte apoptosis in utero
  • Ovaries replaced with fibrous tissue
  • Associated cardiac and renal anomalies
  • Short stature common
Turner Mosaicism (45,X/46,XX)
Spontaneous puberty more common
  • Some follicular development possible
  • Rare spontaneous pregnancy
  • Variable phenotype
46,XY Gonadal Dysgenesis
Prevalence 1:100,000 births
  • Female phenotype (complete form)
  • Mutations in SRY, NR5A1, DHH genes
  • High gonadoblastoma risk
  • Gonadectomy required
Source: UpToDate - Turner Syndrome: Clinical Manifestations and Diagnosis | www.uptodate.com
Primary Ovarian Insufficiency (POI)
POI, formerly called premature ovarian failure, refers to menopause before age 40 years. It typically presents as secondary amenorrhea but can occasionally present as primary amenorrhea.
Key Characteristics
  • Elevated FSH (>40 mIU/mL on two occasions)
  • Low estradiol levels
  • Intermittent ovarian function possible
  • Hot flashes and vaginal dryness common
  • Conception rare but possible
Common Etiologies
  • Chromosomal abnormalities (Turner syndrome)
  • Fragile X premutation (FMR1)
  • Autoimmune oophoritis
  • Chemotherapy/radiation
  • Genetic mutations (increasing recognition)
Source: UpToDate - Pathogenesis and Causes of Spontaneous Primary Ovarian Insufficiency | www.uptodate.com
Polycystic Ovary Syndrome (PCOS)
PCOS is one of the most common endocrine disorders in women, accounting for approximately 30% of secondary amenorrhea cases and up to 50% of oligomenorrhea cases.
Ovulatory Dysfunction
Oligomenorrhea or amenorrhea
Androgen Excess
Clinical or biochemical hyperandrogenism
Polycystic Ovaries
On ultrasound examination
Metabolic Issues
Insulin resistance, obesity
Diagnosis requires 2 of 3 Rotterdam criteria: ovulatory dysfunction, hyperandrogenism, polycystic ovaries (after excluding other causes).
Source: UpToDate - Diagnosis of Polycystic Ovary Syndrome in Adults | www.uptodate.com
Uterine
Outflow Tract Disorders
Congenital abnormalities of the female reproductive organs account for approximately 20% of primary amenorrhea cases. These anatomical defects prevent normal menstrual flow.
Imperforate Hymen
Simplest defect causing primary amenorrhea
  • Cyclic pelvic pain
  • Hematocolpos
  • Easy surgical correction
Transverse Vaginal Septum
Can occur at any level
  • Similar presentation to imperforate hymen
  • Requires surgical excision
  • Accounts for 3% of cases
Müllerian Agenesis (MRKH)
Congenital absence of vagina
  • Variable uterine development
  • Normal ovarian function
  • Incidence 1:4,000-10,000
Source: UpToDate - Congenital Anomalies of the Hymen and Vagina | www.uptodate.com
Intrauterine Adhesions (Asherman Syndrome)
Asherman syndrome is the only uterine cause of secondary amenorrhea, resulting from acquired scarring of the endometrial lining.
Etiology and Risk Factors
  • Postpartum hemorrhage with D&C
  • Endometrial infection
  • Multiple uterine procedures
  • Severe endometritis
Clinical Presentation
  • Amenorrhea or hypomenorrhea
  • Normal hormone levels
  • History of uterine instrumentation
  • Infertility
Diagnosis is confirmed by hysterosalpingography or hysteroscopy. Treatment involves hysteroscopic lysis of adhesions followed by estrogen therapy.
Source: UpToDate - Intrauterine Adhesions: Clinical Manifestation and Diagnosis | www.uptodate.com
Endocrine
Receptor Abnormalities and Enzyme Deficiencies
Rare disorders of steroid synthesis and receptor function can cause primary amenorrhea through various mechanisms affecting the hypothalamic-pituitary-ovarian-adrenal axis.
1
Complete Androgen Insensitivity (CAIS)
46,XY with female phenotype due to androgen receptor defects. Normal female external genitalia, absent uterus, male-range testosterone. Testes produce müllerian-inhibiting substance causing regression of internal structures.
2
5-Alpha-Reductase Deficiency
46,XY unable to convert testosterone to dihydrotestosterone. Ambiguous genitalia at birth, virilization at puberty. Normal testosterone but deficient DHT-dependent masculinization.
3
17-Alpha-Hydroxylase Deficiency
Rare CYP17 gene defect affecting both 46,XX and 46,XY individuals. Decreased cortisol and sex steroids, excess mineralocorticoids. Presents with hypertension and lack of pubertal development.
4
P450 Oxidoreductase Deficiency
Affects multiple cytochrome P450 enzymes. Variable presentation from severe virilization to amenorrhea with infertility. May present with Antley-Bixler syndrome features.
Source: UpToDate - Uncommon Congenital Adrenal Hyperplasias | www.uptodate.com
Thyroid
Thyroid Disease and Amenorrhea
Both hypothyroidism and hyperthyroidism can be associated with menstrual cycle disorders, including amenorrhea and oligomenorrhea.

Important Note: Profound hypothyroidism can cause hyperprolactinemia due to increased TRH, which stimulates both TSH and prolactin secretion. Always treat hypothyroidism before pursuing pituitary imaging for hyperprolactinemia.
Source: UpToDate - Clinical Manifestations of Hypothyroidism | www.uptodate.com
Evaluation
Initial Clinical Evaluation
A systematic approach to history and physical examination is essential for identifying the cause of amenorrhea and guiding appropriate laboratory testing.
Comprehensive History
Assess pubertal development, family history, growth patterns, stress, weight changes, exercise habits, medications, symptoms of hyperandrogenism, galactorrhea, and signs of hypothalamic-pituitary disease.
Physical Examination
Measure height, weight, BMI. Assess Tanner staging, examine for hirsutism, acne, striae, vitiligo, Turner syndrome features. Perform careful genital examination for anatomical abnormalities.
Pelvic Ultrasound
Confirm presence or absence of uterus, ovaries, and cervix. Evaluate for vaginal or cervical outlet obstruction. Assess endometrial thickness as marker of estrogen status.
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Laboratory Testing Strategy
Initial laboratory evaluation should be systematic and cost-effective, focusing on the most common and treatable causes of amenorrhea.
01
Rule Out Pregnancy
Serum β-hCG is the most sensitive test. Always perform first, even with negative home test.
02
Core Hormone Panel
FSH, prolactin, TSH, and estradiol measured on random day (or day 3-5 if menses occurs).
03
Assess Hyperandrogenism
If clinical signs present: total testosterone, DHEAS, 17-hydroxyprogesterone.
04
Additional Testing
Based on initial results: karyotype, imaging, specialized endocrine tests.
Source: UpToDate - Evaluation and Management of Secondary Amenorrhea | www.uptodate.com
Interpreting FSH Levels
Serum FSH concentration is a critical test that helps categorize amenorrhea and guide further evaluation.
High FSH (>40 mIU/mL)
Indicates primary ovarian insufficiency. Next steps:
  • Obtain karyotype (Turner syndrome, 46,XY)
  • Test for FMR1 premutation
  • Check antiadrenal antibodies
  • Evaluate for autoimmune conditions
  • If 46,XY: gonadectomy required
Low or Normal FSH
Suggests hypothalamic-pituitary disorder or PCOS. Consider:
  • Assess estrogen status
  • Measure LH (FSH:LH ratio)
  • Evaluate for functional causes
  • Consider pituitary MRI if indicated
  • Screen for systemic illness
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Algorithm
Diagnostic Algorithm: Primary Amenorrhea
A systematic approach based on the presence or absence of the uterus and breast development, combined with FSH levels, efficiently narrows the differential diagnosis.
The presence or absence of a uterus is the single most important initial finding. This, combined with FSH levels and testosterone measurements, guides the diagnostic pathway.
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Diagnostic Algorithm: Secondary Amenorrhea
After excluding pregnancy, the evaluation of secondary amenorrhea follows a systematic approach based on initial hormone testing results.
Initial testing with prolactin, TSH, FSH, and estradiol efficiently categorizes most cases and directs appropriate further evaluation and management.
Source: UpToDate - Evaluation and Management of Secondary Amenorrhea | www.uptodate.com
Management
Management Goals and Principles
Treatment of amenorrhea is multifaceted and should be individualized based on the underlying cause and patient goals.
Correct Underlying Pathology
Address reversible causes when possible (e.g., weight restoration, treat thyroid disease, remove prolactinoma)
Achieve Fertility
Provide appropriate fertility treatments when desired (ovulation induction, assisted reproduction)
Prevent Complications
Hormone replacement for bone health, manage metabolic risks, prevent endometrial hyperplasia
Optimize Quality of Life
Address symptoms, provide psychological support, ensure appropriate counseling
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Management of Functional Hypothalamic Amenorrhea
Treatment focuses on addressing the underlying energy deficit and preventing long-term complications, particularly bone loss.
Lifestyle Interventions
  • Increase caloric intake to match energy expenditure
  • Reduce exercise intensity if excessive
  • Weight gain to BMI >18.5 kg/m²
  • Nutritional counseling
  • Cognitive behavioral therapy
Medical Management
  • Estrogen-progestin therapy for bone health
  • Calcium and vitamin D supplementation
  • Regular bone density monitoring

Important: Hormonal contraceptives do not provide the same bone benefit as physiologic estrogen-progestin replacement therapy in this population.
Source: UpToDate - Functional Hypothalamic Amenorrhea: Evaluation and Management | www.uptodate.com
Management of Hyperprolactinemia
Treatment depends on the cause of hyperprolactinemia, tumor size (if present), and patient goals regarding fertility.
Dopamine Agonist Therapy
First-line treatment for prolactinomas
  • Cabergoline: preferred (better efficacy, tolerability)
  • Bromocriptine: alternative option
  • Normalizes prolactin in 80-90% of cases
  • Shrinks tumor in most patients
Surgical Management
Reserved for specific situations
  • Drug-resistant or intolerant cases
  • Macroadenomas with mass effect
  • Apoplexy
  • Transsphenoidal approach
Radiation Therapy
Rarely needed
  • Aggressive tumors
  • Failed medical and surgical therapy
  • Long-term risk of hypopituitarism
Source: UpToDate - Management of Hyperprolactinemia | www.uptodate.com
Management of Primary Ovarian Insufficiency
Women with POI require hormone replacement therapy to prevent long-term complications and may need fertility counseling.
Hormone Replacement
Essential for bone and cardiovascular health
  • Estrogen-progestin therapy until age 50-51
  • Transdermal estradiol preferred
  • Cyclic or continuous progestin
  • Higher doses than typical menopause HRT
Bone Health
Prevent osteoporosis
  • Baseline bone density assessment
  • Calcium 1200-1500 mg/day
  • Vitamin D 800-1000 IU/day
  • Weight-bearing exercise
Fertility Options
Counseling and assisted reproduction
  • Spontaneous pregnancy rare but possible
  • Donor oocyte IVF most successful
  • Oocyte cryopreservation if mosaic Turner
  • Psychological support important
Source: UpToDate - Management of Primary Ovarian Insufficiency | www.uptodate.com
Management of PCOS
Treatment is individualized based on patient goals and addresses metabolic, reproductive, and cosmetic concerns.
Lifestyle Modification
First-line therapy for all patients with PCOS, particularly those who are overweight or obese. Weight loss of 5-10% can restore ovulation and improve metabolic parameters.
Menstrual Regulation
Combined oral contraceptives for endometrial protection and cycle regulation. Cyclic progestins if contraceptives contraindicated. Prevents endometrial hyperplasia.
Fertility Treatment
Letrozole first-line for ovulation induction. Clomiphene citrate alternative. Metformin adjunct therapy. Gonadotropins for resistant cases. IVF if needed.
Metabolic Management
Screen for diabetes, dyslipidemia, NAFLD. Metformin for glucose intolerance. Statins if indicated. Lifestyle counseling ongoing.
Source: UpToDate - Treatment of Polycystic Ovary Syndrome in Adults | www.uptodate.com
Surgical
Surgical Management of Anatomical Abnormalities
Surgical intervention is required for certain anatomical causes of amenorrhea, with timing and approach depending on the specific condition.
Imperforate Hymen
Simple hymenotomy performed as soon as diagnosis is made after menarche to allow passage of menstrual blood. Excellent prognosis with normal fertility.
Transverse Vaginal Septum
Surgical excision of septum with creation of vaginal continuity. More complex than hymenotomy. May require staged procedures depending on location and thickness.
Vaginal Agenesis
Creation of neovagina delayed until patient is emotionally mature. Options include progressive dilation (Frank method) or surgical creation (McIndoe procedure). Requires ongoing maintenance.
Gonadectomy
Required when Y chromosome material present due to gonadoblastoma risk. Timing: after puberty in CAIS, promptly in gonadal dysgenesis. Followed by hormone replacement.
Source: UpToDate - Congenital Uterine Anomalies: Surgical Repair | www.uptodate.com
Management of Intrauterine Adhesions
Asherman syndrome requires specialized treatment to restore endometrial function and menstrual flow.
Hysteroscopic Lysis
  • Direct visualization and division of adhesions
  • May require multiple procedures
  • Fluoroscopic guidance for severe cases
  • Careful technique to avoid perforation
Post-Operative Management
  • High-dose estrogen therapy (2-3 months)
  • Intrauterine device or balloon catheter
  • Antibiotics to prevent infection
  • Follow-up hysteroscopy to assess healing
Outcomes
Success rates vary by severity:
  • Mild adhesions: 70-90% pregnancy rate
  • Moderate adhesions: 50-70% pregnancy rate
  • Severe adhesions: 20-40% pregnancy rate
  • Recurrence common in severe cases
Source: UpToDate - Intrauterine Adhesions: Clinical Manifestation and Diagnosis | www.uptodate.com
Fertility
Fertility Considerations in Amenorrhea
Many women with amenorrhea desire fertility, and modern reproductive technologies offer various options depending on the underlying cause.
Functional Hypothalamic Amenorrhea
Weight restoration often restores ovulation. If persistent, pulsatile GnRH (where available) or gonadotropins effective. Adequate nutrition crucial during pregnancy.
PCOS
Letrozole first-line for ovulation induction (better than clomiphene). Metformin as adjunct. Gonadotropins for resistant cases. IVF if needed. Good prognosis overall.
Primary Ovarian Insufficiency
Spontaneous pregnancy rare but possible. Donor oocyte IVF most successful option. Oocyte cryopreservation if diagnosed early. Genetic counseling important.

There was an error generating this image

Müllerian Agenesis
Normal ovarian function allows oocyte retrieval. IVF with gestational carrier enables genetic parenthood. Uterine transplantation experimental option.
Source: UpToDate - Management of Primary Ovarian Insufficiency | www.uptodate.com
Bone Health
Bone Health in Hypoestrogenic Amenorrhea
Prolonged hypoestrogenism significantly increases osteoporosis risk. Prevention and treatment are critical components of management.
2-4%
Annual Bone Loss
Without estrogen replacement in young women with amenorrhea
85%
Bone Density Improvement
With physiologic estrogen-progestin replacement therapy
30%
Fracture Risk Increase
In athletes with prolonged amenorrhea and low BMD
Prevention Strategies
  • Physiologic estrogen replacement
  • Calcium 1200-1500 mg/day
  • Vitamin D 800-1000 IU/day
  • Weight-bearing exercise
  • Avoid smoking and excess alcohol
Monitoring
  • Baseline DXA scan at diagnosis
  • Repeat DXA every 1-2 years
  • Earlier if Z-score <-2.0
  • Consider trabecular bone score
Source: UpToDate - Functional Hypothalamic Amenorrhea: Evaluation and Management | www.uptodate.com
Cardiovascular
Cardiovascular Considerations
Prolonged hypoestrogenism may increase cardiovascular risk, particularly in women with premature ovarian insufficiency.
Endothelial Function
Estrogen deficiency impairs endothelial function and arterial compliance. Early hormone replacement may preserve vascular health. Effects most pronounced in POI.
Lipid Profile
Hypoestrogenism associated with unfavorable lipid changes. Increased LDL cholesterol and decreased HDL. Estrogen therapy improves lipid profile.
Long-term Risk
Women with POI have increased cardiovascular mortality if untreated. Hormone therapy until natural menopause age recommended. Benefits outweigh risks in young women.

Special Consideration: Women with Turner syndrome have additional cardiovascular risks including coarctation of the aorta, bicuspid aortic valve, and aortic dissection. Regular cardiac monitoring is essential.
Source: UpToDate - Management of Primary Ovarian Insufficiency | www.uptodate.com
Psychological
Psychological Impact and Support
Amenorrhea, particularly when associated with infertility or gender identity issues, can have significant psychological impact requiring comprehensive support.
Emotional Distress
Diagnosis can cause anxiety, depression, grief over fertility loss
Body Image
Concerns about femininity, sexual identity, physical appearance
Relationship Impact
Strain on partnerships, disclosure challenges, intimacy issues
Support Systems
Professional counseling, peer support groups, family education
Therapeutic Interventions
Cognitive behavioral therapy, acceptance strategies, coping skills
Comprehensive care should include psychological assessment and support, particularly for conditions like Turner syndrome, androgen insensitivity, and müllerian agenesis.
Source: UpToDate - Turner Syndrome: Clinical Manifestations and Diagnosis | www.uptodate.com
Special Cases
Special Populations: Athletes
Female athletes, particularly those in endurance sports and aesthetic sports, are at high risk for functional hypothalamic amenorrhea as part of the Female Athlete Triad.
Risk Factors
  • Endurance sports (running, cycling)
  • Aesthetic sports (gymnastics, ballet)
  • Weight-class sports
  • High training volume
  • Low body fat percentage
  • Restrictive eating patterns
Management Approach
  • Multidisciplinary team (physician, dietitian, psychologist)
  • Increase energy intake
  • Reduce training intensity if needed
  • Address eating disorders
  • Hormone therapy for bone protection
  • Education on long-term risks
Source: UpToDate - Functional Hypothalamic Amenorrhea: Pathophysiology | www.uptodate.com
Special Populations: Adolescents
Evaluation and management of amenorrhea in adolescents requires special considerations regarding normal pubertal development and age-appropriate interventions.
1
Age 13: Evaluation Threshold
Begin evaluation if no secondary sexual characteristics present. Consider constitutional delay, hypogonadotropic hypogonadism, or gonadal dysgenesis.
2
Age 14-15: Primary Amenorrhea
Evaluate if no menarche despite normal pubertal development. Consider outflow tract disorders, PCOS, or functional causes.
3
Post-Menarche: Secondary Amenorrhea
Anovulation common in first 2 years. Investigate if >3 months amenorrhea or >6 months oligomenorrhea after this period.
4
Special Considerations
Age-appropriate counseling, family involvement, bone health critical during peak bone mass accrual, fertility preservation discussions when relevant.
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Cultural
Cultural and Ethical Considerations
Management of amenorrhea, particularly in cases involving differences of sex development, requires cultural sensitivity and ethical awareness.
Gender Identity and DSD
Conditions like androgen insensitivity and 5-alpha-reductase deficiency raise complex issues of gender assignment and identity. Patient autonomy in gender decisions should be respected. Timing of gonadectomy should balance cancer risk with patient preferences.
Disclosure and Privacy
Sensitive information about karyotype, gonadal tissue, and fertility potential requires careful disclosure. Age-appropriate communication essential. Patient privacy must be protected. Family education and support important.
Fertility and Reproductive Choices
Assisted reproductive technologies raise ethical questions about donor gametes, gestational carriers, and genetic screening. Cultural and religious beliefs may influence treatment decisions. Informed consent crucial for all interventions.
Resource Allocation
Access to specialized care, expensive medications, and assisted reproduction varies globally. Equity considerations in treatment recommendations. Cost-effectiveness of different management strategies.
Source: UpToDate - Diagnosis and Treatment of Disorders of the Androgen Receptor | www.uptodate.com
Research
Emerging Research and Future Directions
Ongoing research continues to expand our understanding of amenorrhea and develop new treatment options.
Genetic Discoveries
Next-generation sequencing identifying new genetic causes of POI and gonadal dysgenesis. Mutations in genes involved in meiosis, DNA repair, and folliculogenesis being characterized. Potential for targeted therapies based on genetic etiology.
Regenerative Medicine
Stem cell research exploring ovarian tissue regeneration. In vitro activation of dormant follicles showing promise. Artificial ovary development in experimental stages. Potential to restore fertility in POI.
Uterine Transplantation
Successful pregnancies achieved with uterine transplantation. Potential option for müllerian agenesis and other uterine factor infertility. Ethical and technical challenges remain. Long-term outcomes being studied.
Novel Therapeutics
Kisspeptin analogs for hypothalamic amenorrhea. Selective estrogen receptor modulators for bone health. Improved ovulation induction protocols. Personalized medicine approaches based on phenotype.
Source: UpToDate - Pathogenesis and Causes of Spontaneous Primary Ovarian Insufficiency | www.uptodate.com
Practice Points
Key Clinical Practice Points
Essential takeaways for clinical practice in the evaluation and management of amenorrhea.
1
Always Rule Out Pregnancy First
Even with negative home tests or claims of no sexual activity, measure serum β-hCG before proceeding with evaluation. Pregnancy is the most common cause of secondary amenorrhea.
2
Systematic Approach is Essential
Use a structured algorithm based on presence/absence of uterus, FSH levels, and other key tests. This prevents missed diagnoses and unnecessary testing.
3
Don't Forget Bone Health
Hypoestrogenic amenorrhea causes rapid bone loss. Initiate hormone replacement promptly and monitor bone density. The window for optimal bone mass accrual is limited.
4
Address the Whole Patient
Consider psychological impact, fertility desires, and quality of life. Multidisciplinary care often needed. Patient education and support are crucial components of management.
5
Individualize Treatment
Management should be tailored to the underlying cause, patient age, fertility goals, and preferences. One size does not fit all in amenorrhea management.
Source: UpToDate - Evaluation and Management of Secondary Amenorrhea | www.uptodate.com
Common Pitfalls to Avoid
Awareness of common diagnostic and management errors can improve patient outcomes.
1
Assuming PCOS Without Full Evaluation
PCOS is a diagnosis of exclusion. Must rule out other causes of hyperandrogenism and oligomenorrhea, including thyroid disease, hyperprolactinemia, and androgen-secreting tumors.
2
Ordering Pituitary MRI Prematurely
Confirm hyperprolactinemia with repeat testing before imaging. Rule out hypothyroidism first. Avoid MRI for borderline elevations without clinical correlation.
3
Delaying Hormone Replacement in POI
Young women with POI need hormone therapy immediately to prevent bone loss and cardiovascular complications. Don't wait for "natural" recovery that rarely occurs.
4
Missing Y Chromosome Material
Always obtain karyotype in primary amenorrhea with high FSH. Presence of Y chromosome requires gonadectomy due to malignancy risk. Don't assume 45,X without testing.
5
Inadequate Counseling
Patients need clear information about diagnosis, prognosis, and fertility implications. Psychological support is essential, especially for conditions affecting gender identity or fertility.
Source: UpToDate - Evaluation and Management of Primary Amenorrhea | www.uptodate.com
Case Studies
Clinical Case 1: Functional Hypothalamic Amenorrhea
Presentation
19-year-old competitive runner with 8-month amenorrhea. BMI 17.5 kg/m². Training 60+ miles/week.
Evaluation
  • Negative pregnancy test
  • FSH 3.2 mIU/mL (low-normal)
  • LH 2.1 mIU/mL
  • Estradiol 25 pg/mL (low)
  • Prolactin, TSH normal
  • DXA: Z-score -2.3 lumbar spine
Diagnosis
Functional hypothalamic amenorrhea due to energy deficit from excessive exercise and inadequate caloric intake.
Management
  • Nutritional counseling - increase intake by 500 kcal/day
  • Reduce training volume by 20%
  • Transdermal estradiol 0.1 mg + cyclic progesterone
  • Calcium 1500 mg, vitamin D 1000 IU daily
  • Follow-up DXA in 12 months
Outcome
Menses resumed after 4 months. Bone density improved at 1 year.
Source: UpToDate - Functional Hypothalamic Amenorrhea: Evaluation and Management | www.uptodate.com
Clinical Case 2: Primary Ovarian Insufficiency
Presentation
28-year-old woman with 6-month amenorrhea, hot flashes, night sweats. No prior medical history. Desires future pregnancy.
Evaluation
  • Negative pregnancy test
  • FSH 78 mIU/mL (repeated: 82 mIU/mL)
  • Estradiol <20 pg/mL
  • Karyotype: 46,XX
  • FMR1: normal (28 CGG repeats)
  • Antiadrenal antibodies: negative
  • Pelvic ultrasound: small ovaries, no follicles
Diagnosis
Spontaneous 46,XX primary ovarian insufficiency, etiology unknown.
Management
  • Estradiol 2 mg daily + micronized progesterone 200 mg days 1-12
  • Calcium and vitamin D supplementation
  • Baseline DXA scan
  • Fertility counseling: donor oocyte IVF discussed
  • Psychological support referral
  • Annual monitoring: TSH, glucose, lipids

Learning Point: POI requires prompt hormone replacement to prevent long-term complications. Fertility counseling should be provided early, as spontaneous pregnancy is rare but donor oocyte IVF has excellent success rates.
Source: UpToDate - Management of Primary Ovarian Insufficiency | www.uptodate.com
Clinical Case 3: Turner Syndrome
A 15-year-old girl presents with primary amenorrhea and short stature (height 145 cm, <3rd percentile).
Initial Presentation
No breast development (Tanner stage 1). Webbed neck, shield chest, widely spaced nipples noted. Blood pressure 145/90 mmHg (right arm), 110/70 mmHg (left arm).
Laboratory Results
FSH 95 mIU/mL, LH 42 mIU/mL, estradiol <10 pg/mL. Karyotype: 45,X. Pelvic ultrasound: streak gonads, normal uterus.
Additional Evaluation
Echocardiogram: bicuspid aortic valve, mild coarctation. Renal ultrasound: horseshoe kidney. Hearing test: mild high-frequency loss. Thyroid function normal.
Management Plan
Cardiology referral for coarctation management. Gradual estrogen induction starting with low-dose transdermal estradiol. Growth hormone discontinued (age 15). Calcium/vitamin D supplementation. Multidisciplinary care coordination.
Long-term Follow-up
Annual cardiac monitoring. Transition to adult hormone replacement. Fertility counseling regarding donor oocyte options. Psychological support. Monitoring for associated conditions (diabetes, thyroid disease).
Source: UpToDate - Turner Syndrome: Clinical Manifestations and Diagnosis | www.uptodate.com
Resources
Patient Resources and Support Organizations
Connecting patients with appropriate resources and support networks is an important component of comprehensive care.
Turner Syndrome Society
Education, support groups, and advocacy for individuals with Turner syndrome and their families. Annual conferences and local chapters available.
PCOS Awareness Association
Information, support, and advocacy for women with polycystic ovary syndrome. Online forums and educational materials.
Premature Ovarian Insufficiency Support Groups
Peer support for women experiencing early menopause. Online communities and local meetups available.
UpToDate Patient Education
Evidence-based patient information on amenorrhea, written at appropriate reading levels. "The Basics" and "Beyond the Basics" versions available.
National Eating Disorders Association
Resources for individuals with eating disorders that may contribute to functional hypothalamic amenorrhea. Helpline and treatment referrals.
RESOLVE: The National Infertility Association
Support and advocacy for individuals facing infertility. Information on assisted reproductive technologies and family-building options.
Source: UpToDate - Patient Education Resources | www.uptodate.com
Guidelines
Professional Society Guidelines
Multiple professional organizations have published guidelines on the evaluation and management of amenorrhea.
American Society for Reproductive Medicine (ASRM)
Current Evaluation of Amenorrhea (2006, reaffirmed 2024)
  • Systematic approach to diagnosis
  • Laboratory testing recommendations
  • Management algorithms
Endocrine Society
Clinical Practice Guidelines for PCOS (2013)
  • Diagnostic criteria
  • Screening recommendations
  • Treatment approaches
American Academy of Pediatrics
Menstruation in Girls and Adolescents (2016)
  • Normal menstrual patterns
  • When to evaluate amenorrhea
  • Age-appropriate management
American College of Obstetricians and Gynecologists (ACOG)
Multiple committee opinions and practice bulletins
  • Primary ovarian insufficiency
  • Polycystic ovary syndrome
  • Female athlete triad
Source: UpToDate - Society Guideline Links: Amenorrhea | www.uptodate.com
Summary
Key Takeaways
Essential points to remember about the evaluation and management of amenorrhea.
Systematic Evaluation
Use a structured approach based on pregnancy test, FSH, prolactin, TSH, and presence/absence of uterus to efficiently diagnose the cause of amenorrhea.
Common Causes
Functional hypothalamic amenorrhea (35%), PCOS (30%), and POI (10%) account for majority of secondary amenorrhea. Gonadal dysgenesis most common in primary amenorrhea (43%).
Bone Health Priority
Hypoestrogenic amenorrhea causes rapid bone loss. Prompt hormone replacement essential, especially during adolescence and young adulthood when peak bone mass is accrued.
Individualized Management
Treatment must be tailored to underlying cause, patient age, fertility goals, and preferences. Multidisciplinary care often needed for optimal outcomes.
Comprehensive Care
Address not only the physical aspects but also psychological impact, fertility concerns, and quality of life. Patient education and support are crucial.
Long-term Follow-up
Many causes of amenorrhea require ongoing monitoring and management. Establish clear follow-up plans and coordinate care with appropriate specialists.
Source: UpToDate - Evaluation and Management of Secondary Amenorrhea | www.uptodate.com
Thank You
This comprehensive review of amenorrhea evaluation and management is based on current evidence-based guidelines and clinical practice recommendations.
Key Resources
  • UpToDate Clinical Decision Support
  • American Society for Reproductive Medicine
  • Endocrine Society Guidelines
  • American College of Obstetricians and Gynecologists
For Further Information
Visit www.uptodate.com for the most current evidence-based clinical information and regularly updated topic reviews.

Presenter: Professor Mykhailo Medvediev
Based on: UpToDate Clinical Decision Support Resources
Last Updated: December 2025
Access UpToDate
All content based on UpToDate evidence-based clinical decision support | www.uptodate.com